Inhibition of epileptiform activity by neuropeptide Y in brain tissue from drug-resistant temporal lobe epilepsy patients
Jenny Wickham, Marco Ledri, Johan Bengzon, Bo Jespersen, Lars H Pinborg, Elisabet Englund, David P D Woldbye, My Andersson, Merab Kokaia, Jenny Wickham, Marco Ledri, Johan Bengzon, Bo Jespersen, Lars H Pinborg, Elisabet Englund, David P D Woldbye, My Andersson, Merab Kokaia
Abstract
In epilepsy patients, drug-resistant seizures often originate in one of the temporal lobes. In selected cases, when certain requirements are met, this area is surgically resected for therapeutic reasons. We kept the resected tissue slices alive in vitro for 48 h to create a platform for testing a novel treatment strategy based on neuropeptide Y (NPY) against drug-resistant epilepsy. We demonstrate that NPY exerts a significant inhibitory effect on epileptiform activity, recorded with whole-cell patch-clamp, in human hippocampal dentate gyrus. Application of NPY reduced overall number of paroxysmal depolarising shifts and action potentials. This effect was mediated by Y2 receptors, since application of selective Y2-receptor antagonist blocked the effect of NPY. This proof-of-concept finding is an important translational milestone for validating NPY-based gene therapy for targeting focal drug-resistant epilepsies, and increasing the prospects for positive outcome in potential clinical trials.
Conflict of interest statement
M.K. and D.W. are co-founders and consultants of spin-off company COMBIGENE AB, Sweden. M.K. and D.W. are also inventors on awarded patent pertaining to the data presented (WO2008004972).
Figures
References
- Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet. 2006;367:1087–1100. doi: 10.1016/S0140-6736(06)68477-8.
- Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792–802. doi: 10.1016/S1474-4422(12)70153-9.
- Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279–286. doi: 10.1001/jamaneurol.2017.3949.
- Andersson M, et al. Optogenetic control of human neurons in organotypic brain cultures. Sci. Rep. 2016;6:24818. doi: 10.1038/srep24818.
- Avaliani N, Andersson M, Runegaard AH, Woldbye D, Kokaia M. DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue. Gene Ther. 2016;23:760–766. doi: 10.1038/gt.2016.56.
- Ledri M, et al. Differential effect of neuropeptides on excitatory synaptic transmission in human epileptic hippocampus. J. Neurosci. 2015;35:9622–9631. doi: 10.1523/JNEUROSCI.3973-14.2015.
- Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296:659–660. doi: 10.1038/296659a0.
- Marksteiner J, Ortler M, Bellmann R, Sperk G. Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat. Neurosci. Lett. 1990;112:143–148. doi: 10.1016/0304-3940(90)90193-D.
- Vezzani A, Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: An endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides. 2004;38:245–252. doi: 10.1016/j.npep.2004.05.004.
- Sørensen AT, et al. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol. 2009;215:328–333. doi: 10.1016/j.expneurol.2008.10.015.
- Nikitidou Ledri L, et al. Translational approach for gene therapy in epilepsy: Model system and unilateral overexpression of neuropeptide Y and Y2 receptors. Neurobiol. Dis. 2016;86:52–61. doi: 10.1016/j.nbd.2015.11.014.
- Powell KL, et al. Gene therapy mediated seizure suppression in genetic generalised epilepsy: neuropeptide Y overexpression in a rat model. Neurobiol. Dis. 2018;113:23–32. doi: 10.1016/j.nbd.2018.01.016.
- Richichi C, et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 2004;24:3051–3059. doi: 10.1523/JNEUROSCI.4056-03.2004.
- Klapstein GJ, Colmers WF. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J Neurophysiol. 1997;78:1651–61. doi: 10.1152/jn.1997.78.3.1651.
- El Bahh B, et al. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y2 and not Y5 receptors. Eur. J. Neurosci. 2005;22:1417–1430. doi: 10.1111/j.1460-9568.2005.04338.x.
- El Bahh B, Cao JQ, Beck-Sickinger AG, Colmers WF. Blockade of neuropeptide Y2receptors and suppression of NPY’s anti-epileptic actions in the rat hippocampal slice by BIIE0246. Br. J. Pharmacol. 2002;136:502–509. doi: 10.1038/sj.bjp.0704751.
- Klapstein, G. J. & Colmers, W. F. 4-Aminopyridine and low Ca2+ differentiate presynaptic inhibition mediated by neuropeptide. October 470–474 (1992).
- Greber S, Schwarzer C, Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 1994;113:737–740. doi: 10.1111/j.1476-5381.1994.tb17055.x.
- Silva AP, Pinheiro PS, Carvalho CM, Zimmer J. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 2003;17:1118–1120. doi: 10.1096/fj.02-0885fje.
- Patrylo PR, van den Pol AN, Spencer DD, Williamson A. NPY inhibits glutamatergic excitation in the epileptic human dentate gyrus. J. Neurophysiol. 1999;82:478–483. doi: 10.1152/jn.1999.82.1.478.
- Woldbye DPD, et al. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain. 2010;133:2778–2788. doi: 10.1093/brain/awq219.
- Jandová K, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain. 2006;129:3290–3306. doi: 10.1093/brain/awl218.
- Sandow N, et al. Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: No significant impact of P-glycoprotein and multidrug resistance-associated proteins. Front. Neurol. 2015;6:1–18. doi: 10.3389/fneur.2015.00030.
- Hsiao MC, et al. An in vitro seizure model from human hippocampal slices using multi-electrode arrays. J. Neurosci. Methods. 2015;244:154–163. doi: 10.1016/j.jneumeth.2014.09.010.
- Jones RSG, da Silva AB, Whittaker RG, Woodhall GL, Cunningham MO. Human brain slices for epilepsy research: Pitfalls, solutions and future challenges. J. Neurosci. Methods. 2016;260:221–232. doi: 10.1016/j.jneumeth.2015.09.021.
- Traub RD, Colling SB, Jefferys JG. Cellular mechanisms of 4-aminopyridine-induced synchronized after-discharges in the rat hippocampal slice. J. Physiol. 1995;489:127–140. doi: 10.1113/jphysiol.1995.sp021036.
- Avoli M, et al. Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro. Prog. Neurobiol. 2002;68:167–201. doi: 10.1016/S0301-0082(02)00077-1.
- Buckle PJ, Haas HL. Enhancement of synaptic transmission by 4-aminopyridine in hippocampal slices of the rat. The Journal of Physiology. 1982;326:109–122. doi: 10.1113/jphysiol.1982.sp014180.
- Rutecki PA, Lebeda FJ, Johnston D. 4-Aminopyridine produces epileptiform activity in hippocampus and enhances synaptic excitation and inhibition. J. Neurophysiol. 1987;57:1911–1924. doi: 10.1152/jn.1987.57.6.1911.
- Gabriel S, et al. Stimulus and potassium-induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis. J. Neurosci. 2004;24:10416–10430. doi: 10.1523/JNEUROSCI.2074-04.2004.
- Schiller Y. Activation of a Calcium-Activated Cation Current During Epileptiform Discharges and Its Possible Role in Sustaining Seizure-Like Events in Neocortical Slices. J. Neurophysiol. 2004;92:862–872. doi: 10.1152/jn.00972.2003.
- Sanon NT, Pelletier JG, Carmant L, Lacaille JC. Interneuron subtype specific activation of mGluR15 during epileptiform activity in hippocampus. Epilepsia. 2010;51:1607–1618. doi: 10.1111/j.1528-1167.2010.02689.x.
- Lin CH, et al. Effects of anti-epileptic drugs on spreading depolarization-induced epileptiform activity in mouse hippocampal slices. Sci. Rep. 2017;7:1–14. doi: 10.1038/s41598-016-0028-x.
- Noè F, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008;131:1506–1515. doi: 10.1093/brain/awn079.
- Huberfeld G, et al. Glutamatergic pre-ictal discharges emerge at the transition to seizure in human epilepsy. Nat. Neurosci. 2011;14:627–634. doi: 10.1038/nn.2790.
- Misgeld, A. U., Deisz, R. A., Dodt, H. U. & Lux, H. D. The Role of Chloride Transport in Postsynaptic Inhibition of Hippocampal Neurons. 232, 1413–1415 (1986).
- Andersen P, Dingledine R, Gjerstad L, Langmoen IA, Mosfeldt Laursen A. Two different responses of hippocampal pyramidal cells to application of gamma-amino butyric acid. J. Physiol. 1980;305:279–296. doi: 10.1113/jphysiol.1980.sp013363.
- Avoli M, de Curtis M. GABAergic synchronization in the limbic system and its role in the generation of epileptiform activity. Prog. Neurobiol. 2011;95:104–132. doi: 10.1016/j.pneurobio.2011.07.003.
- Blümcke I, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia. 2013;54:1315–1329. doi: 10.1111/epi.12220.
- Wickham J, et al. Prolonged life of human acute hippocampal slices from temporal lobe epilepsy surgery. Sci. Rep. 2018;8:4158. doi: 10.1038/s41598-018-22554-9.
Source: PubMed